Novel tool can estimate number of T cells in cancer tumours
Researchers have developed a new method that can rapidly count the number of T cells in a tumour, helping to predict patient response to therapies.
List view / Grid view
Researchers have developed a new method that can rapidly count the number of T cells in a tumour, helping to predict patient response to therapies.
Researchers are investigating how high-intensity focused ultrasound (HIFU) can work on a cellular level to treat a range of cancers.
A team have found that two DNA changes appear to predict acute lymphoblastic leukaemia, illuminating genetic understanding of the disease.
A newly developed blood vessel model can mimic the states of health and disease, paving the way for cardiovascular drug advancements.
A novel synthetic “switch” has been developed that could hold the key to revolutionary smart insulin therapy for diabetic patients.
To ensure that new drugs are effective and have as little toxicity as possible, they first need to be tested in model systems before entering clinical trials. In this Q&A, Dr Takanori Takebe outlines his research into liver organoids derived from stem cells that can be used to test new…
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
Novel organoid models of cervical cancer and a healthy human cervix have been developed to study the condition and its progression.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
Researchers have developed a personalised medicine platform that could advance genomic medicine research for cancer.
The field of oncology has successfully applied precision medicine approaches to diagnosis and treatment. Success has been driven by a growing understanding of the underlying biology of cancer; the emergence of innovative tools and technologies for biomarker identification and detection; and considerable advocacy by patients, physicians and policymakers that has…
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.
Research into drug targets for sleeping sickness parasite T. brucei has characterised the inosine-5'-monophosphate dehydrogenase (IMPDH) enzyme, providing a possible novel avenue for therapies.
Modern day oncology therapies have seen significant innovation in the last decade. It is high time we commit to using biomarkers that are driven by rational design and the latest computational methods.
The systematic successful treatment of cancer still eludes us and in an effort to refine this area of targeted medicine, Lauri Paasonen and colleagues explore the potential of using patient-derived cells (PDCs) for devising a personalised treatment strategy for solid tumours.